Exendin-4 Inhibits Matrix Metalloproteinase-9 Activation and Reduces Infarct Growth After Focal Cerebral Ischemia in Hyperglycemic Mice

Stroke

Volumn 47, Issue 5, 2016, Pages 1328-1335

  Kuroki, Takuma ^a   Tanaka, Ryota ^a   Shimada, Yoshiaki ^b   Yamashiro, Kazuo ^a   Ueno, Yuji ^a   Shimura, Hideki ^b   Urabe, Takao ^b   Hattori, Nobutaka ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY URAYASU HOSPITAL   (Japan)

Author keywords

brain ischemia; glucagon like peptide 1; hyperglycemia; insulin; matrix metalloproteinase 9; tumor necrosis factor alpha

Indexed keywords

BIOLOGICAL MARKER; EXENDIN 4; GELATINASE B; GLUCOSE; INSULIN; TUMOR NECROSIS FACTOR ALPHA; ANTIDIABETIC AGENT; PEPTIDE; VENOM;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME INHIBITION; GLUCOSE BRAIN LEVEL; HYPERGLYCEMIA; INSULIN TREATMENT; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; INFARCTION, MIDDLE CEREBRAL ARTERY; PATHOLOGY;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MATRIX METALLOPROTEINASE 9; MICE, INBRED C57BL; PEPTIDES; VENOMS;

EID: 84961219357     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.116.012934     Document Type: Article

References (43)

1. Szczudlik A, Slowik A, Turaj W, Wyrwicz-Petkow U, Pera J, Dziedzic T, et al. Transient hyperglycemia in ischemic stroke patients. J Neurol Sci. 2001;189:105-111.
2. Williams LS, Rotich J, Qi R, Fineberg N, Espay A, Bruno A, et al. Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology. 2002;59:67-71.
3. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke. 2001;32:2426-2432.
4. Shimoyama T, Kimura K, Uemura J, Saji N, Shibazaki K. Elevated glucose level adversely affects infarct volume growth and neurological deterioration in non-diabetic stroke patients, but not diabetic stroke patients. Eur J Neurol. 2014;21:402-410. doi: 10.1111/ene.12280.
5. Kawai N, Keep RF, Betz AL. Hyperglycemia and the vascular effects of cerebral ischemia. Stroke. 1997;28:149-154.
6. Martín A, Rojas S, Chamorro A, Falcón C, Bargalló N, Planas AM. Why does acute hyperglycemia worsen the outcome of transient focal cerebral ischemia? Role of corticosteroids, inflammation, and protein O-glycosylation. Stroke. 2006;37:1288-1295. doi: 10.1161/01. STR.0000217389.55009.f8.
7. Elgebaly MM, Ogbi S, Li W, Mezzetti EM, Prakash R, Johnson MH, et al. Neurovascular injury in acute hyperglycemia and diabetes: a comparative analysis in experimental stroke. Transl Stroke Res. 2011;2:391-398. doi: 10.1007/s12975-011-0083-3.
8. Won SJ, Tang XN, Suh SW, Yenari MA, Swanson RA. Hyperglycemia promotes tissue plasminogen activator-induced hemorrhage by Increasing superoxide production. Ann Neurol. 2011;70:583-590. doi: 10.1002/ana.22538.
9. Bellolio MF, Gilmore RM, Ganti L. Insulin for glycaemic control in acute ischaemic stroke. Cochrane Database Syst Rev. 2014;1:CD005346. doi: 10.1002/14651858.CD005346.pub4.
10. MacDougall NJ, Muir KW. Hyperglycaemia and infarct size in animal models of middle cerebral artery occlusion: systematic review and metaanalysis. J Cereb Blood Flow Metab. 2011;31:807-818. doi: 10.1038/jcbfm.2010.210.
11. Gray CS, Hildreth AJ, Sandercock PA, O'Connell JE, Johnston DE, Cartlidge NE, et al; GIST Trialists Collaboration. Glucose-potassiuminsulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol. 2007;6:397-406. doi: 10.1016/S1474-4422(07)70080-7.
12. Finfer S, Heritier S; NICE Study Management Committee and SUGAR Study Executive Committee. The NICE-SUGAR (Normoglycaemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation) Study: statistical analysis plan. Crit Care Resusc. 2009;11:46-57.
13. Griesdale DE, de Souza RJ, van Dam RM, Heyland DK, Cook DJ, Malhotra A, et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ. 2009;180:821-827. doi: 10.1503/cmaj.090206.
14. Dave KR, Tamariz J, Desai KM, Brand FJ, Liu A, Saul I, et al. Recurrent hypoglycemia exacerbates cerebral ischemic damage in streptozotocin-induced diabetic rats. Stroke. 2011;42:1404-1411. doi: 10.1161/STROKEAHA.110.594937.
15. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131-2157. doi: 10.1053/j. gastro.2007.03.054.
16. Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem. 1993;268:19650-19655.
17. Koska J, Schwartz EA, Mullin MP, Schwenke DC, Reaven PD. Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recentonset type 2 diabetes. Diabetes Care. 2010;33:1028-1030. doi: 10.2337/dc09-1961.
18. Hogan AE, Gaoatswe G, Lynch L, Corrigan MA, Woods C, O'Connell J, et al. Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia. 2014;57:781-784. doi: 10.1007/s00125-013-3145-0.
19. Ceriello A, Novials A, Ortega E, Canivell S, La Sala L, Pujadas G, et al. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care. 2013;36:2346-2350. doi: 10.2337/dc12-2469.
20. Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A. 2009;106:1285-1290. doi: 10.1073/pnas.0806720106.
21. Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Aβ oligomers. J Clin Invest. 2012;122:1339-1353. doi: 10.1172/JCI57256.
22. Teramoto S, Miyamoto N, Yatomi K, Tanaka Y, Oishi H, Arai H, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2011;31:1696-1705. doi: 10.1038/jcbfm.2011.51.
23. Lee CH, Yan B, Yoo KY, Choi JH, Kwon SH, Her S, et al. Ischemiainduced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia. J Neurosci Res. 2011;89:1103-1113. doi: 10.1002/jnr.22596.
24. Briyal S, Gulati K, Gulati A. Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats. Brain Res. 2012;1427:23-34. doi: 10.1016/j.brainres.2011.10.026.
25. Hara H, Huang PL, Panahian N, Fishman MC, Moskowitz MA. Reduced brain edema and infarction volume in mice lacking the neuronal isoform of nitric oxide synthase after transient MCA occlusion. J Cereb Blood Flow Metab. 1996;16:605-611. doi: 10.1097/00004647-199607000-00010.
26. Hamilton MG, Tranmer BI, Auer RN. Insulin reduction of cerebral infarction due to transient focal ischemia. J Neurosurg. 1995;82:262-268. doi: 10.3171/jns.1995.82.2.0262.
27. Li Y, Chopp M, Chen J, Wang L, Gautam SC, Xu YX, et al. Intrastriatal transplantation of bone marrow nonhematopoietic cells improves functional recovery after stroke in adult mice. J Cereb Blood Flow Metab. 2000;20:1311-1319. doi: 10.1097/00004647-200009000-00006.
28. Türeyen K, Vemuganti R, Sailor KA, Dempsey RJ. Infarct volume quantification in mouse focal cerebral ischemia: a comparison of triphenyltetrazolium chloride and cresyl violet staining techniques. J Neurosci Methods. 2004;139:203-207. doi: 10.1016/j. jneumeth.2004.04.029.
29. Strbian D, Karjalainen-Lindsberg ML, Tatlisumak T, Lindsberg PJ. Cerebral mast cells regulate early ischemic brain swelling and neutrophil accumulation. J Cereb Blood Flow Metab. 2006;26:605-612. doi: 10.1038/sj.jcbfm.9600228.
30. Miyamoto N, Zhang N, Tanaka R, Liu M, Hattori N, Urabe T. Neuroprotective role of angiotensin II type 2 receptor after transient focal ischemia in mice brain. Neurosci Res. 2008;61:249-256. doi: 10.1016/j.neures.2008.03.003.
31. Tanaka R, Komine-Kobayashi M, Mochizuki H, Yamada M, Furuya T, Migita M, et al. Migration of enhanced green fluorescent protein expressing bone marrow-derived microglia/macrophage into the mouse brain following permanent focal ischemia. Neuroscience. 2003;117:531-539.
32. Hallenbeck JM. The many faces of tumor necrosis factor in stroke. Nat Med. 2002;8:1363-1368. doi: 10.1038/nm1202-1363.
33. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta. 2003;329:23-38.
34. Ennis SR, Keep RF. Effect of sustained-mild and transient-severe hyperglycemia on ischemia-induced blood-brain barrier opening. J Cereb Blood Flow Metab. 2007;27:1573-1582. doi: 10.1038/sj.jcbfm.9600454.
35. Kamada H, Yu F, Nito C, Chan PH. Influence of hyperglycemia on oxidative stress and matrix metalloproteinase-9 activation after focal cerebral ischemia/reperfusion in rats: relation to blood-brain barrier dysfunction. Stroke. 2007;38:1044-1049. doi: 10.1161/01.STR.0000258041.75739. cb.
36. Guo J, Dhaliwall JK, Chan KK, Ghanim H, Al Koudsi N, Lam L, et al. In vivo effect of insulin to decrease matrix metalloproteinase-2 and -9 activity after arterial injury. J Vasc Res. 2013;50:279-288. doi: 10.1159/000351611.
37. Schuyler CA, Ta NN, Li Y, Lopes-Virella MF, Huang Y. Insulin treatment attenuates diabetes-increased atherosclerotic intimal lesions and matrix metalloproteinase 9 expression in apolipoprotein E-deficient mice. J Endocrinol. 2011;210:37-46. doi: 10.1530/JOE-10-0420.
38. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.
39. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-1705. doi: 10.1016/S0140-6736(06)69705-5.
40. Chen YT, Tsai TH, Yang CC, Sun CK, Chang LT, Chen HH, et al. Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction. J Transl Med. 2013;11:270. doi: 10.1186/1479-5876-11-270.
41. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes. 2010;59:1030-1037. doi: 10.2337/db09-1694.
42. Hossmann KA. The two pathophysiologies of focal brain ischemia: implications for translational stroke research. J Cereb Blood Flow Metab. 2012;32:1310-1316. doi: 10.1038/jcbfm.2011.186.
43. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, et al; STAIR Group. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009;40:2244-2250. doi: 10.1161/STROKEAHA.108.541128.